Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cardiology (Mahwah, N.J.) Jg. 40; H. 3; S. 138 - 148
Hauptverfasser:	Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	New York Wiley Periodicals, Inc 01.03.2017 John Wiley & Sons, Inc
Schlagworte:	Cardiovascular Diseases - drug therapy Cardiovascular Diseases - epidemiology Clinical trials Dose-Response Relationship, Drug Double-Blind Method Eicosapentaenoic Acid - administration & dosage Eicosapentaenoic Acid - analogs & derivatives Female Follow-Up Studies France - epidemiology General clinical cardiology/adult Health risk assessment Heart attacks Humans Incidence Lipidology Low density lipoprotein Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Prospective Studies Quebec - epidemiology Risk Factors Time Factors Treatment Outcome Trial Designs Triglycerides United Kingdom - epidemiology United States - epidemiology Clinical trials General clinical cardiology/adult Lipidology
ISSN:	0160-9289, 1932-8737, 1932-8737
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!